Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Ulcerated Lichen Planus after Adjuvant Use of Programmed Cell Death-1-Inhibitor: A Case Report and Systematic Review of the Literature.

Literature DB >> 34043014

Ulcerated Lichen Planus after Adjuvant Use of Programmed Cell Death-1-Inhibitor: A Case Report and Systematic Review of the Literature.

Anne-Charlotte Niesert¹, Anne Guertler, Olga Schutti, Laura Engels, Michael Flaig, Lars E French, Max Schlaak, Markus Reinholz.

Abstract

Entities: Chemical

Keywords: anti-PD-1; anti-PD-L1; immune-related adverse event; melanoma; pembrolizumab; lichen planus

Mesh：

Substances：
B7-H1 Antigen
Nivolumab

Year: 2021 PMID： 34043014 PMCID： PMC9380279 DOI： 10.2340/00015555-3840

Source DB: PubMed Journal: Acta Derm Venereol ISSN： 0001-5555 Impact factor: 3.875

× No keyword cloud information.

11 in total

1. Bullous lichen planus and anti-programmed cell death-1 therapy: Case report and literature review.

Authors: C de Lorenzi; R André; A Vuilleumier; G Kaya; M Abosaleh
Journal: Ann Dermatol Venereol Date: 2020-01-22 Impact factor: 0.777

2. Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma.

Authors: Alexander M M Eggermont; Christian U Blank; Mario Mandala; Georgina V Long; Victoria Atkinson; Stéphane Dalle; Andrew Haydon; Mikhail Lichinitser; Adnan Khattak; Matteo S Carlino; Shahneen Sandhu; James Larkin; Susana Puig; Paolo A Ascierto; Piotr Rutkowski; Dirk Schadendorf; Rutger Koornstra; Leonel Hernandez-Aya; Michele Maio; Alfonsus J M van den Eertwegh; Jean-Jacques Grob; Ralf Gutzmer; Rahima Jamal; Paul Lorigan; Nageatte Ibrahim; Sandrine Marreaud; Alexander C J van Akkooi; Stefan Suciu; Caroline Robert
Journal: N Engl J Med Date: 2018-04-15 Impact factor: 91.245

3. Clinical epidemiology and treatment of lichen planus: A retrospective review of 2 tertiary care centers.

Authors: Zachary Schwager; Marleigh Stern; Jeffrey Cohen; Alisa Femia
Journal: J Am Acad Dermatol Date: 2019-04-17 Impact factor: 11.527

Review 4. Dermatologic complications of anti-PD-1/PD-L1 immune checkpoint antibodies.

Authors: Vincent Sibaud; Nicolas Meyer; Laurence Lamant; Emmanuelle Vigarios; Julien Mazieres; Jean Pierre Delord
Journal: Curr Opin Oncol Date: 2016-07 Impact factor: 3.645

5. A new frontier in treatment of advanced melanoma: Redefining clinical management in the era of immune checkpoint inhibitors.

Authors: Oren Levine; Tahira Devji; Feng Xie
Journal: Hum Vaccin Immunother Date: 2017-05-08 Impact factor: 3.452

Review 6. Dermatologic Reactions to Immune Checkpoint Inhibitors : Skin Toxicities and Immunotherapy.

Authors: Vincent Sibaud
Journal: Am J Clin Dermatol Date: 2018-06 Impact factor: 7.403

7. A systematic review on the emerging association between the occurrence of immune-related adverse events and clinical outcomes with checkpoint inhibitors in advanced cancer patients.

Authors: Alessio Cortellini; Sebastiano Buti; Veronica Agostinelli; Melissa Bersanelli
Journal: Semin Oncol Date: 2019-11-07 Impact factor: 4.929

8. European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment - Update 2019.

Authors: Claus Garbe; Teresa Amaral; Ketty Peris; Axel Hauschild; Petr Arenberger; Lars Bastholt; Veronique Bataille; Veronique Del Marmol; Brigitte Dréno; Maria Concetta Fargnoli; Jean-Jacques Grob; Christoph Höller; Roland Kaufmann; Aimilios Lallas; Celeste Lebbé; Josep Malvehy; Mark Middleton; David Moreno-Ramirez; Giovanni Pellacani; Philippe Saiag; Alexander J Stratigos; Ricardo Vieira; Iris Zalaudek; Alexander M M Eggermont
Journal: Eur J Cancer Date: 2019-12-19 Impact factor: 9.162